Aims:This study is aimed at finding out a logical solution for perimenopausal menorrhagia in normal or bulky uterus.Settings and Design:The study is carried out at a tertiary care hospital at Odisha. In our setup, nearly 900 hysterectomies are done per year out of which 60% are for menorrhagia with bulky uterus.Subjects and Methods:There were sixty cases of menorrhagia between the ages of 40 and 55 years who completed child bearing treated with ormeloxifene. Their endometrial thickness (ET) and hemoglobin (Hb) level were determined at the start of the study and also at 6 months and compared. At 1 year from the start of treatment, patients' satisfaction and status of menstrual cycle were reassessed.Statistical Analysis Used:Age and parity variables were expressed as mean ± standard deviation and range. We used the paired samples t-test to estimate the mean, median, range, P and t value. All statistical analyses were performed using SPSS software version 11.5 (IBM Corp) and tests of statistical significance were two-sided and differences were taken as significant when P < 0.05.Results:After 1 year of follow-up, 90% of patients found to be amenorrhoic and only two out of them presented with mild irritability and vasomotor complaints which resolved with counseling and placebo therapy. There was a significant reduction (P < 0.0001) in ET and rise in Hb level (P < 0.0001).Conclusions:Ormeloxifene is a safe drug which can be used to treatment of perimenopausal bleeding with minimal focal pathology.

Background: Pregnancy is a unique physiological diabetogenic state characterised by increased insulin resistance that ensures adequate supply of nutrients to the developing fetus. The insulin sensitivity falls to upto 50 percent in the late pregnancy. Thus insulin resistance and the resultant hyperinsulinemia are the characteristics features that are evident in the normal pregnancy during third trimester. In Hypertensive disorders of pregnancy (HDP), there is exacerbation of the physiological insulin resistance that occurs in normal pregnancy resulting in increased fasting serum insulin level. Methods: This is a case control study conducted on 90 antenatal women, during the study period of one and half years (from December 2020 to June 2022) in IMS and SUM Hospital, Bhubaneswar. With informed written consent and after fulfilling the criterias, 60 normotensive patients were chosen as controls and 30 pregnant patients with hypertensive disorders of pregnancy were chosen as cases. After 8 hours of overnight fasting, 2ml of blood is drawn and processed by CMIA technology to detect fasting serum insulin levels. The mean fasting serum insulin levels were compared between the cases and the controls. Results: The mean fasting serum insulin level of controls was found to be 9.27 and the mean fasting serum insulin level of cases was found to be 15.01 which was higher than controls. This was found to be statistically significant with a P value of 0.000. Conclusions: Increased fasting serum insulin level is observed in women with HDP than normotensive pregnant women.